AU2012271453B2 - Anti-inflammatory pharmaceutical products - Google Patents

Anti-inflammatory pharmaceutical products Download PDF

Info

Publication number
AU2012271453B2
AU2012271453B2 AU2012271453A AU2012271453A AU2012271453B2 AU 2012271453 B2 AU2012271453 B2 AU 2012271453B2 AU 2012271453 A AU2012271453 A AU 2012271453A AU 2012271453 A AU2012271453 A AU 2012271453A AU 2012271453 B2 AU2012271453 B2 AU 2012271453B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
residue
present disclosure
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012271453A
Other languages
English (en)
Other versions
AU2012271453A1 (en
Inventor
Angelo P. Consalvo
Jesmond DALLI
Nozer M. Mehta
Mauro Perretti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resother Pharma AS
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Publication of AU2012271453A1 publication Critical patent/AU2012271453A1/en
Assigned to ENTERIS BIOPHARMA, INC. reassignment ENTERIS BIOPHARMA, INC. Request for Assignment Assignors: UGP THERAPEUTICS, INC.
Assigned to RESOTHER PHARMA APS reassignment RESOTHER PHARMA APS Request for Assignment Assignors: ENTERIS BIOPHARMA, INC.
Application granted granted Critical
Publication of AU2012271453B2 publication Critical patent/AU2012271453B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2012271453A 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products Active AU2012271453B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161497270P 2011-06-15 2011-06-15
US61/497,270 2011-06-15
PCT/US2012/042699 WO2012174397A2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products
US13/524,381 2012-06-15
US13/524,381 US9102753B2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Publications (2)

Publication Number Publication Date
AU2012271453A1 AU2012271453A1 (en) 2013-12-19
AU2012271453B2 true AU2012271453B2 (en) 2017-07-06

Family

ID=47357770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012271453A Active AU2012271453B2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Country Status (12)

Country Link
US (2) US9102753B2 (https=)
EP (2) EP3533457B1 (https=)
JP (1) JP6069663B2 (https=)
CN (1) CN103764669B (https=)
AU (1) AU2012271453B2 (https=)
BR (1) BR112013032088B1 (https=)
CA (1) CA2839298C (https=)
DK (1) DK2720707T3 (https=)
ES (1) ES2712805T3 (https=)
HU (1) HUE042929T2 (https=)
PL (1) PL2720707T3 (https=)
WO (1) WO2012174397A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
PL4200319T3 (pl) 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
CN118891273A (zh) 2022-02-23 2024-11-01 雷索特制药股份有限公司 膜联蛋白a1衍生的多肽类似物
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163578A1 (en) * 2004-10-01 2009-06-25 University Of Medicine And Dentistry Of New Jersey Novel modification of immunomodulatory protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
US6086018A (en) 1997-12-09 2000-07-11 Mcdonnell Douglas Corporation Interlocking assembly system for an aircraft cabin
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物
US8691764B2 (en) * 2007-03-28 2014-04-08 The Research Foundation For The State University Of New York Inhibitors of NF-κB activity
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US8940697B2 (en) * 2009-10-16 2015-01-27 Duke University Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with Annexin A1 short peptide
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163578A1 (en) * 2004-10-01 2009-06-25 University Of Medicine And Dentistry Of New Jersey Novel modification of immunomodulatory protein

Also Published As

Publication number Publication date
EP3533457B1 (en) 2021-08-11
CN103764669B (zh) 2017-08-15
ES2712805T3 (es) 2019-05-14
US20150315256A1 (en) 2015-11-05
US9102753B2 (en) 2015-08-11
BR112013032088B1 (pt) 2020-11-24
PL2720707T3 (pl) 2019-06-28
HUE042929T2 (hu) 2019-07-29
CA2839298C (en) 2021-05-18
CN103764669A (zh) 2014-04-30
DK2720707T3 (en) 2019-04-08
AU2012271453A1 (en) 2013-12-19
CA2839298A1 (en) 2012-12-20
EP3533457A1 (en) 2019-09-04
EP2720707B1 (en) 2018-12-19
WO2012174397A2 (en) 2012-12-20
US10072055B2 (en) 2018-09-11
WO2012174397A3 (en) 2013-02-28
JP6069663B2 (ja) 2017-02-01
US20130072446A1 (en) 2013-03-21
JP2014519526A (ja) 2014-08-14
EP2720707A4 (en) 2015-05-06
BR112013032088A2 (pt) 2016-11-22
EP2720707A2 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
AU2012271453B2 (en) Anti-inflammatory pharmaceutical products
CA2372821C (en) Antimicrobial theta defensins and methods of using same
EP2480567B1 (en) Thrombin c-terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
JP7621728B2 (ja) プロテアーゼ活性化受容体２のモジュレーター
CA2588145A1 (en) Novel antimicrobial peptides
US20200129582A1 (en) Novel peptides and peptidomimetics
CN107106643A (zh) 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽
KR102780883B1 (ko) 신규한 항염증성 펩타이드 및 이의 용도
JP5982394B2 (ja) ＭＭＰ基質で連結したβｉｇ−ｈ３断片ペプチド及びそのリウマチ性関節炎予防及び治療用途
KR20210147362A (ko) Nlrx1 유래의 신규한 항염증성 펩타이드 및 이의 용도
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
JP2018507853A (ja) 代謝障害の治療薬としてのデルマトポンチン
WO2013163567A2 (en) Novel alpha-helical peptidomimetic inhibitors and methods using same
HK1242610A1 (en) Methods for reducing cd36 expression
CA2178927A1 (en) Peptide inhibitors of cxc intercrine molecules
HK1197994B (en) Methods for reducing cd36 expression
WO2013023166A2 (en) Hapivirins and diprovirins
HK1197994A (en) Methods for reducing cd36 expression

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ENTERIS BIOPHARMA, INC.

Free format text: FORMER APPLICANT(S): UGP THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: RESOTHER PHARMA APS

Free format text: FORMER APPLICANT(S): ENTERIS BIOPHARMA, INC.

FGA Letters patent sealed or granted (standard patent)